Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Deferred Taxes (2019 - 2021)

Historic Deferred Taxes for Amphastar Pharmaceuticals (AMPH) over the last 5 years, with Q4 2021 value amounting to $2.8 million.

  • Amphastar Pharmaceuticals' Deferred Taxes fell 2678.95% to $2.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $4.6 million, marking a year-over-year increase of 272839.51%. This contributed to the annual value of $17.9 million for FY2024, which is 4208.94% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Deferred Taxes of $2.8 million as of Q4 2021, which was down 2678.95% from $3.8 million recorded in Q4 2020.
  • In the past 5 years, Amphastar Pharmaceuticals' Deferred Taxes ranged from a high of $5.3 million in Q4 2019 and a low of -$2.0 million during Q3 2020
  • Moreover, its 3-year median value for Deferred Taxes was $2.8 million (2021), whereas its average is $1.7 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Deferred Taxes plummeted by 2870.54% in 2020 and then crashed by 2678.95% in 2021.
  • Quarter analysis of 3 years shows Amphastar Pharmaceuticals' Deferred Taxes stood at $5.3 million in 2019, then fell by 28.71% to $3.8 million in 2020, then fell by 26.79% to $2.8 million in 2021.
  • Its Deferred Taxes stands at $2.8 million for Q4 2021, versus $3.8 million for Q4 2020 and -$2.0 million for Q3 2020.